To Effects of ZincorespTM Syrup in Children Aged 2- 12 Years Having Respiratory Disorders and Infections.
- Conditions
- Health Condition 1: J00-J99- Diseases of the respiratory system
- Registration Number
- CTRI/2024/02/063048
- Lead Sponsor
- apex laboratories private limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Children between 2-12 years of age of any gender.
2. Children having recurrent episodes of any of the following:
- Fever associated with respiratory tract infections (RTI)
- URTI (rhinitis, pharyngitis, laryngitis, otitis media, influenza)
- LRTI (pneumonia, bronchitis, and bronchiolitis)
- Bronchial asthma
- COPD
- SARS-CoV-2
- Combined allergic rhinitis and asthma syndrome (CARAS)
- Pulmonary tuberculosis
3.Parents are willing to give consent for the child’s participation in study.
1. Any evidence of malignancy.
2. History and clinical findings suggestive of metabolic diseases
3. History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
4. History of respiratory tract surgery.
5. Known diagnosis of congenital cardiac defects.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in symptoms of respiratory disorders and/or infectionsTimepoint: Baseline to Week 12
- Secondary Outcome Measures
Name Time Method